diabetes obesity News
-
GI Dynamics Announces Approval of the I-STEP Clinical Study in India
BOSTON & HYDERABAD, India--( )-- GI Dynamics Inc., a medical device company that isBUSINESS WIRE developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, is pleased to announce that it has received regulatory approval to begin enrollment in the I-STEP clinical trial in India. I-STEP is a multi-center, randomized, pivotal study evaluating the safety and ...
-
GI Dynamics Announces the Presentation of Updated Data Sets at the 2022 Meeting of the American Diabetes Association
Data demonstrate favorable safety and efficacy profile for the duodenal jejunal bypass liner (DJBL) technology BOSTON — July 13, 2022 — GI Dynamics® Inc., a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce positive data from the Association of British Clinical Diabetologists (ABCD) Worldwide ...
-
GI Dynamics Announces Final Data from the ENDO Trial, a Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity.
Initial results show the duodenal jejunal bypass liner (DJBL) technology met overall glycemic control efficacy and SAE related device removal safety endpoints Findings Presented at DDW 2022 BOSTON – June 15, 2022 – GI Dynamics, a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, announced results from a ...
-
Novo Nordisk to Acquire Dicerna
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna, a biopharmaceutical company focused on the development of investigational ribonucleic acid interference (RNAi) therapeutics, for $38.25 per share in cash, which represents a total equity value of $3.3 billion and a premium of ...
-
Expansion of Topical Wound Oxygen (TWO2) Product Family Extends Treatment to Chronic Wound Patients with Larger Limbs, Venous and Diabetic Foot Ulcers
AOTI Inc. announced today an eagerly anticipated expansion of its unique multi-modality Topical Wound Oxygen (TWO2) therapy product family. The addition of a new larger extremity-chamber to the company’s peripheral vascular disease (PVD) focused product line, allows for the application of TWO2 treatments for many more patients suffering from costly nonhealing chronic wounds. Especially ...
-
EPA, NIEHS Leaders Celebrate Children`s Health Month, 15 Years of Children`s Health Research
Tuesday, October 29th, U.S. Environmental Protection Agency (EPA)Administrator Gina McCarthy and National Institute of Environmental Health Sciences (NIEHS) Director Linda Birnbaum will kick off a conference celebrating 15 years of children's health research. The conference will highlight the progress made over more than a decade of children's research and the benefits of a more sustainable and ...
-
Study: BPA May Increase Risk of Heart Disease
A recent study published in Circulation has linked heart disease with bisphenol A (BPA), the controversial industrial chemical that is ubiquitous in plastics, resins, paint, can linings, and other products, reports Time. Examining data from a long-running British health survey, researchers discovered that people who had heart disease also tended to have higher urinary concentrations of BPA. ...
-
Sodexo health and wellness: embracing meatless mondays
Sodexo Blog - Health & Wellness by Chris Elam Here at Meatless Monday, we’re delighted that Sodexo is embracing the Meatless Monday movement in your client facilities around the country. We’re particularly pleased that you’ve chosen to focus on the health & wellness benefits, in line with your Better Tomorrow Plan, because it’s holistic changes which can improve ...
By 3BL Media
-
How the brain-eye connection aims to make memory loss a souvenir
In fact, nearly 40% of people over the age of 65 suffer from some form of memory loss. Understanding the causes of memory loss There’s currently no cure for Alzheimer’s or Alzheimer’s related dementia, early detection can give patients more control over how they manage their overall well-being. That includes managing their brain health to reduce certain risk factors, ...
-
Outpatient measurement of arterial stiffness in patients with type 2 diabetes and obesity
BACKGROUND: Pulse wave velocity (PWV) is a marker of arterial stiffness. The aim of the present study was to compare PWV in patients with type 2 diabetes mellitus (T2DM) or obesity and healthy subjects in an outpatient setting. METHODS: A cross-sectional study was conducted in patients with obesity without T2DM (n = 37), T2DM without obesity (n = 40), T2DM plus ...
By Axelife SAS
-
Consuming Canned Soups Elevates BPA Levels, Study Finds
Harvard researchers have found that people who ate one serving of canned food daily over the course of five days had a tenfold increase of bisphenol-A, or BPA, in their bodies, according to the New York Times. Past research indicates that BPA can mimic the hormone estrogen, and thus it is considered to be an endocrine disruptor. Some scientists claim that BPA is not a health threat, but ...
-
Can herbicides increase pancreatic cancer risk?
There is only a small chance of recovering from pancreatic cancer. This type of cancer has been linked to a number of risk factors, including smoking, but a new study suggests that pancreatic cancer may also be associated with exposure to certain herbicides. Other risk factors, in addition to smoking, that have been associated with a greater chance of developing pancreatic cancer include ...
-
Aurealis Therapeutics Pioneering Multiple Drug Producing Bacteria Aup-16 Dosed to The First Diabetic Foot Ulcer Patient in The Phase 1-2a Trial
Aurealis Therapeutics, a private clinical-stage biopharmaceutical company developing AUP-16, the three-in-one combination biologic drug for chronic non-healing wounds and regenerative diseases, announced today that the first diabetic foot ulcer (DFU) patient has been dosed with AUP-16. The trial is performed in non-healing DFU patients and is designed to evaluate the safety, tolerability and ...
-
National Toxicology Program workshop: role of environmental chemicals in the development of diabetes and obesity
The National Toxicology Program (NTP) is hosting this workshop on Jan. 11-13, 2011, because there is a growing body of research showing that chemicals in our environment may be contributing to diabetes and obesity worldwide, and that chemical exposures need to be considered along with nutrition and diet. Six chemical classes will be discussed at the workshop, including 1) arsenic and other ...
-
Creative Enzymes Upgrades Multiple Diagnostic Enzyme Products for Clinical and Diagnostic Research
Creative Enzymes, the world’s leading diagnostic enzyme production company, has been committed to providing customers with various enzyme products and services for medical and research diagnosis. Relying on its professional team and the most advanced technology, as well as high-quality products and services, it has gained solid reputation. Recently, Creative Enzymes has announced multiple ...
-
CD BioSciences Introduces mTOR Pathway for Metabolism Research
CD BioSciences, a US-based life science research product supplier and CRO, recently launches mTOR Pathway to the life science community for research applications. These new signaling pathways and other metabolic signaling pathways, such as Insulin Signaling Pathway and AMPK pathway, will support researchers in all aspects of cell death study. A metabolic pathway is a series of metabolic chemical ...
-
Our Partnership with Cerba HealthCare
The Cerba HealthCare Group and METAFORA biosystems are to cooperate in the deployment of METAFORA proprietary technology in the field of metabolomics for diagnostics purposes. The technological platform developed by METAFORA enables the evaluation of cells’ energy needs in connection with patients’ health. “The investigation into altered metabolic functions for the ...
-
Lipidomics Bioinformation Analysis Now Available by Creative Proteomics’s Lipidomics Platform
As a division of Creative Proteomics, Lipidomics is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnological and pharmaceutical companies. The company has recently announced the launch of a fully-developed lipidomics bioinformation analysis service to screen differential lipid molecules and analyze their pathways, ...
-
Regor and Lilly Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders
Eli Lilly and Company (NYSE: LLY) and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders. Under the terms of the agreement, Lilly will have a license to select Regor intellectual property with an option to extend the license. Lilly will be responsible for clinical ...
-
GI Dynamics Appoints New Chief Executive Officer and Board of Directors
BOSTON — November 5, 2020 — GI Dynamics® Inc. (“GI Dynamics” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, has appointed Joseph Virgilio as president and chief executive officer of GI Dynamics, Mark Lerdal as chairman of the Board of Directors (“the Board”) and ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you